CN114846006B - 杂环化合物及其制备方法和用途 - Google Patents

杂环化合物及其制备方法和用途 Download PDF

Info

Publication number
CN114846006B
CN114846006B CN202080086811.1A CN202080086811A CN114846006B CN 114846006 B CN114846006 B CN 114846006B CN 202080086811 A CN202080086811 A CN 202080086811A CN 114846006 B CN114846006 B CN 114846006B
Authority
CN
China
Prior art keywords
compound
cancer
xrpd
pattern
peaks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080086811.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN114846006A (zh
Inventor
代星
江岳恒
刘艳琴
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yifang Biotechnology Shanghai Co ltd
Original Assignee
Yifang Biotechnology Shanghai Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yifang Biotechnology Shanghai Co ltd filed Critical Yifang Biotechnology Shanghai Co ltd
Priority to CN202410490957.2A priority Critical patent/CN118459459A/zh
Publication of CN114846006A publication Critical patent/CN114846006A/zh
Application granted granted Critical
Publication of CN114846006B publication Critical patent/CN114846006B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202080086811.1A 2019-12-18 2020-12-17 杂环化合物及其制备方法和用途 Active CN114846006B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410490957.2A CN118459459A (zh) 2019-12-18 2020-12-17 杂环化合物及其制备方法和用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/CN2019/126230 WO2021120045A1 (en) 2019-12-18 2019-12-18 Heterocyclic compounds, preparation methods and uses thereof
CNPCT/CN2019/126230 2019-12-18
PCT/CN2020/137276 WO2021121330A1 (en) 2019-12-18 2020-12-17 Heterocyclic compounds, preparation methods and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410490957.2A Division CN118459459A (zh) 2019-12-18 2020-12-17 杂环化合物及其制备方法和用途

Publications (2)

Publication Number Publication Date
CN114846006A CN114846006A (zh) 2022-08-02
CN114846006B true CN114846006B (zh) 2024-04-26

Family

ID=76476909

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080086811.1A Active CN114846006B (zh) 2019-12-18 2020-12-17 杂环化合物及其制备方法和用途
CN202410490957.2A Pending CN118459459A (zh) 2019-12-18 2020-12-17 杂环化合物及其制备方法和用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202410490957.2A Pending CN118459459A (zh) 2019-12-18 2020-12-17 杂环化合物及其制备方法和用途

Country Status (8)

Country Link
US (3) US11241437B2 (cg-RX-API-DMAC10.html)
EP (1) EP4077311A4 (cg-RX-API-DMAC10.html)
JP (1) JP7710449B2 (cg-RX-API-DMAC10.html)
KR (1) KR102965826B1 (cg-RX-API-DMAC10.html)
CN (2) CN114846006B (cg-RX-API-DMAC10.html)
AU (1) AU2020410474A1 (cg-RX-API-DMAC10.html)
CA (1) CA3161852A1 (cg-RX-API-DMAC10.html)
WO (2) WO2021120045A1 (cg-RX-API-DMAC10.html)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019217307A1 (en) 2018-05-07 2019-11-14 Mirati Therapeutics, Inc. Kras g12c inhibitors
AU2019338207B2 (en) 2018-09-10 2025-01-02 Mirati Therapeutics, Inc. Combination therapies
US12208099B2 (en) 2018-09-10 2025-01-28 Mirati Therapeutics, Inc. Combination therapies
CA3112043A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
SMT202500028T1 (it) 2018-09-10 2025-03-12 Mirati Therapeutics Inc Terapie combinate
WO2020085504A1 (ja) 2018-10-26 2020-04-30 大鵬薬品工業株式会社 光照射ザンドマイヤー反応を用いたクロロアゾールカルボキシレート誘導体の製造方法
US12377101B2 (en) 2018-12-05 2025-08-05 Mirati Therapeutics, Inc. Combination therapies
WO2020146613A1 (en) 2019-01-10 2020-07-16 Mirati Therapeutics, Inc. Kras g12c inhibitors
CN114615981B (zh) 2019-08-29 2024-04-12 米拉蒂治疗股份有限公司 Kras g12d抑制剂
CN114761012B (zh) 2019-09-24 2025-03-21 米拉蒂治疗股份有限公司 组合疗法
MD4051678T2 (en) 2019-10-28 2026-07-31 Merck Sharp & Dohme Llc Small molecule inhibitors of the KRAS G12C mutant
WO2021085653A1 (en) 2019-10-31 2021-05-06 Taiho Pharmaceutical Co., Ltd. 4-aminobut-2-enamide derivatives and salts thereof
EP4067343A4 (en) 2019-11-29 2024-01-03 Taiho Pharmaceutical Co., Ltd. NEW PHENOLIC COMPOUND OR SALT THEREOF
PH12022551513A1 (en) 2019-12-20 2023-04-24 Mirati Therapeutics Inc Sos1 inhibitors
CN114671866A (zh) * 2020-12-25 2022-06-28 苏州泽璟生物制药股份有限公司 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用
WO2021215544A1 (en) 2020-04-24 2021-10-28 Taiho Pharmaceutical Co., Ltd. Kras g12d protein inhibitors
US12702658B2 (en) 2020-04-24 2026-08-11 Taiho Pharmaceutical Co., Ltd. Anticancer combination therapy with N-(1-acryloyl-azetidin-3-yl)-2-((1H-indazol-3-yl)amino)methyl)-1H-imidazole-5-carboxamide inhibitor of KRAS-G12C
WO2021249563A1 (zh) * 2020-06-12 2021-12-16 苏州泽璟生物制药股份有限公司 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用
US12655160B2 (en) 2020-08-04 2026-06-16 Mirati Therapeutics, Inc. KRAS G12D inhibitors
EP4208261A1 (en) 2020-09-03 2023-07-12 Revolution Medicines, Inc. Use of sos1 inhibitors to treat malignancies with shp2 mutations
EP4210833A4 (en) 2020-09-11 2024-09-11 Mirati Therapeutics, Inc. CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR
IL301298A (en) 2020-09-15 2023-05-01 Revolution Medicines Inc Indole derivatives as RAS inhibitors in cancer therapy
EP4216951B1 (en) 2020-09-22 2026-04-01 Mirati Therapeutics, Inc. Kras g12d inhibitors
WO2022066805A1 (en) 2020-09-23 2022-03-31 Erasca, Inc. Tricyclic pyridones and pyrimidones
WO2022109487A1 (en) 2020-11-23 2022-05-27 Merck Sharp & Dohme Corp. Spirocyclic-substituted 6,7-dihydro-pyrano[2,3-d]pyrimidine inhibitors of kras g12c mutant
EP4262807A4 (en) 2020-12-15 2025-04-23 Mirati Therapeutics, Inc. Azachinazoline pan-KRAS inhibitors
WO2022133038A1 (en) 2020-12-16 2022-06-23 Mirati Therapeutics, Inc. Tetrahydropyridopyrimidine pan-kras inhibitors
US20230107642A1 (en) 2020-12-18 2023-04-06 Erasca, Inc. Tricyclic pyridones and pyrimidones
US12697337B2 (en) 2021-03-11 2026-08-04 InventisBio Co., Ltd. Solid dispersions
PE20240088A1 (es) 2021-05-05 2024-01-16 Revolution Medicines Inc Inhibidores de ras
IL308195A (en) 2021-05-05 2024-01-01 Revolution Medicines Inc RAS inhibitors for cancer treatment
WO2022246069A1 (en) 2021-05-19 2022-11-24 Teva Pharmaceuticals International Gmbh Process for preparation of sotorasib and solid state form thereof
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
TW202340214A (zh) 2021-12-17 2023-10-16 美商健臻公司 做為shp2抑制劑之吡唑并吡𠯤化合物
AU2022421224A1 (en) 2021-12-22 2024-06-20 The Regents Of The University Of California Covalently binding inhibitors of g12s, g12d and/or g12e mutants of k-ras gtpase
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
EP4536364A1 (en) 2022-06-10 2025-04-16 Revolution Medicines, Inc. Macrocyclic ras inhibitors
CN117462553A (zh) * 2022-07-20 2024-01-30 益方生物科技(上海)股份有限公司 药物组合产品以及组合疗法
AU2023377064A1 (en) 2022-11-09 2025-05-22 Revolution Medicines, Inc. Compounds, complexes, and methods for their preparation and of their use
CN121487738A (zh) 2023-03-30 2026-02-06 锐新医药公司 诱导ras gtp水解的组合物和其用途
CN121487951A (zh) 2023-04-07 2026-02-06 锐新医药公司 大环ras抑制剂
WO2024211712A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
EP4695261A1 (en) 2023-04-14 2026-02-18 Revolution Medicines, Inc. Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
AU2024251341A1 (en) 2023-04-14 2025-10-16 Revolution Medicines, Inc. Crystalline forms of a ras inhibitor
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
KR20260096846A (ko) 2023-10-20 2026-06-24 머크 샤프 앤드 돔 엘엘씨 Kras 단백질의 소분자 억제제
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors
CN120154618B (zh) * 2025-05-15 2025-11-18 正大天晴药业集团股份有限公司 格索雷塞用于治疗肺癌的用途或其药物组合物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201906821A (zh) * 2017-05-22 2019-02-16 美商安進公司 Kras g12c抑制劑及其使用方法
TW201922739A (zh) * 2017-09-08 2019-06-16 美商安進公司 Kras g12c抑制劑以及其使用方法
WO2019213516A1 (en) * 2018-05-04 2019-11-07 Amgen Inc. Kras g12c inhibitors and methods of using the same
WO2020233592A1 (en) * 2019-05-21 2020-11-26 Inventisbio Shanghai Ltd. Heterocyclic compounds, preparation methods and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20190338A (es) 2016-12-22 2019-09-09 Amgen Inc Inhibidores de kras g12c y métodos para su uso
CN108658972A (zh) 2017-03-28 2018-10-16 中国海洋大学 一种取代内酰胺类化合物及其制备方法和用途
JP7369719B2 (ja) * 2018-06-12 2023-10-26 アムジエン・インコーポレーテツド KRas G12C阻害剤及びそれを使用する方法
WO2020097537A2 (en) 2018-11-09 2020-05-14 Genentech, Inc. Fused ring compounds
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法
CN110256421A (zh) 2019-06-26 2019-09-20 微境生物医药科技(上海)有限公司 Kras-g12c抑制剂
CN111377918B (zh) 2019-11-29 2021-03-02 苏州信诺维医药科技有限公司 一种kras抑制剂化合物
CN111205286B (zh) 2020-01-13 2022-12-13 中科苏州药物研究院 作为kras g12c突变蛋白抑制剂的腈甲基哌嗪类衍生物及其应用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201906821A (zh) * 2017-05-22 2019-02-16 美商安進公司 Kras g12c抑制劑及其使用方法
TW201922739A (zh) * 2017-09-08 2019-06-16 美商安進公司 Kras g12c抑制劑以及其使用方法
WO2019213516A1 (en) * 2018-05-04 2019-11-07 Amgen Inc. Kras g12c inhibitors and methods of using the same
WO2020233592A1 (en) * 2019-05-21 2020-11-26 Inventisbio Shanghai Ltd. Heterocyclic compounds, preparation methods and uses thereof
CN112585129A (zh) * 2019-05-21 2021-03-30 益方生物科技(上海)股份有限公司 杂环化合物,其制备方法和用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Discovery of a Covalent Inhibitor of KRASG12C (AMG 510) for the Treatment of Solid Tumors;Brian A. Lanman, et al.;J. Med. Chem.;第63卷(第1期);第52-65页 *

Also Published As

Publication number Publication date
US20220226328A1 (en) 2022-07-21
US11241437B2 (en) 2022-02-08
AU2020410474A1 (en) 2022-06-23
US20210260067A1 (en) 2021-08-26
JP7710449B2 (ja) 2025-07-18
US12246020B2 (en) 2025-03-11
CN114846006A (zh) 2022-08-02
WO2021120045A1 (en) 2021-06-24
WO2021121330A1 (en) 2021-06-24
CA3161852A1 (en) 2021-06-24
US11865115B2 (en) 2024-01-09
EP4077311A1 (en) 2022-10-26
EP4077311A4 (en) 2023-11-22
JP2023506308A (ja) 2023-02-15
US20240156820A1 (en) 2024-05-16
KR102965826B1 (ko) 2026-05-14
CN118459459A (zh) 2024-08-09
KR20220118478A (ko) 2022-08-25

Similar Documents

Publication Publication Date Title
KR102965826B1 (ko) 헤테로고리 화합물, 이의 제조 방법 및 이의 용도
AU2017335242C1 (en) Pyridine compound
TW202110836A (zh) 固態形式
KR101829595B1 (ko) 3-(1-{3-[5-(1-메틸-피페리딘-4일메톡시)-피리미딘-2-일]-벤질}-6-옥소-1,6-디히드로-피리다진-3-일)-벤조니트릴 히드로클로라이드 염의 신규한 다형체 및 이의 제조 방법
JP2019518776A (ja) Egfr阻害剤としてのアニリンピリミジン化合物の結晶
CA3059283A1 (en) C5-anilinoquinazoline compounds and their use in treating cancer
US10550101B2 (en) Crystalline forms of mesylate salt of pyridinyl amino pyrimidine derivative, preparation methods therefor, and applications thereof
JP2018502882A (ja) 2−(5−(3−フルオロフェニル)−3−ヒドロキシピコリンアミド)酢酸の固体形態、その組成物及び使用
CN111989099A (zh) 作为cdk4和cdk6抑制剂的2h-吲唑衍生物及其治疗用途
US12116374B2 (en) Solid forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
TWI820182B (zh) 四氫哌喃基胺基-吡咯并嘧啶酮化合物的固體形式
CN117729921A (zh) 作为pd1/pd-l1抑制剂的化合物及其方法
HK40072166B (en) Heterocyclic compounds, preparation methods and uses thereof
HK40072166A (en) Heterocyclic compounds, preparation methods and uses thereof
TW202311267A (zh) 咪唑烷酮類化合物的多晶型物、包含其的藥物組合物、其製備方法及其應用
TW202342041A (zh) 一種藥物組合物及所含活性成分化合物的製備方法
KR20190026910A (ko) 4-시아노-n-(2-(4,4-다이메틸사이클로헥스-1-엔-1-일)-6-(2,2,6,6-테트라메틸테트라하이드로-2h-피란-4-일)피리딘-3-일)-1h-이미다졸-2-카르복스아미드의 결정질 형태
WO2025231053A1 (en) Solid forms of 6-chloro-3-[(1r)-1-[3,6-dimethyl-2-(2-methylindazol-5-yl)-4-oxo-chromen-8-yl]ethoxy]pyridine-2-carboxamide
HK40109564A (en) Novel pharmaceutical salts and polymorphic forms of an erbb and btk inhibitor
TW202519524A (zh) 固態形式
WO2024255845A1 (zh) 一类蛋白降解剂及其药物组合物和用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40072166

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
EE01 Entry into force of recordation of patent licensing contract
EE01 Entry into force of recordation of patent licensing contract

Application publication date: 20220802

Assignee: CHIA TAI TIANQING PHARMACEUTICAL GROUP Co.,Ltd.

Assignor: Yifang Biotechnology (Shanghai) Co.,Ltd.

Contract record no.: X2023990000968

Denomination of invention: Heterocyclic compounds and their preparation methods and applications

License type: Exclusive License

Record date: 20231207

GR01 Patent grant
GR01 Patent grant